MiMedx Group, Inc vs MacroGenics, Inc. — Valuation Comparison 2026
Access all valuation models for MDXG vs MGNX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →MDXG scores higher with a 8.6/10 quality rating vs MGNX's 6.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing MiMedx Group, Inc (MDXG) and MacroGenics, Inc. (MGNX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
MDXG currently trades at $3.67 with a QOC of 8.6/10, while MGNX trades at $4.21 with a QOC of 6.2/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).